Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.66 |
| ▸ | METAP1 | P53582 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16691536 | 1.00 | ACHE (0.66) | ACHEMETAP1TSHRCYP19A1NOS3 | |
| SCHEMBL11776080 | 0.81 | ACHE (0.61) | ACHEMETAP1TSHRCYP19A1NOS3 | |
| SCHEMBL4938272 | 0.79 | ACHE (1.00) | ACHEMETAP1TSHRCYP19A1NOS3 | |
| SCHEMBL9752693 | 0.79 | ACHE (1.00) | ACHEMETAP1TSHRCYP19A1NOS3 | |
| SCHEMBL354925 | 0.79 | ACHE (1.00) | ACHEMETAP1TSHRCYP19A1NOS3 | |
| SCHEMBL13866434 | 0.79 | ACHE (1.00) | ACHEMETAP1TSHRCYP19A1NOS3 | |
| SCHEMBL1200699 | 0.78 | ACHE (0.56) | ACHEMETAP1TSHRNOS3NOS2 | |
| SCHEMBL1699526 | 0.78 | ACHE (0.58) | ACHEMETAP1TSHRCYP19A1NOS3 | |
| Hydrochloric Acid SCHEMBL7403735 | 0.78 | ACHE (0.96) | ACHEMETAP1TSHRCYP19A1 | |
| Dimethylamine SCHEMBL8159682 | 0.77 | ACHE (0.85) | ACHEMETAP1TSHRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109912397-A | One kind is together with difluoro substituted-tetrahydro naphthalene ketone compounds and preparation method thereof | 上海应用技术大学 | 2019-06-21 | — | — | CN | disclosed |
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | disclosed |
| EP-2094680-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008076336-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| EP-0103990-A1 | Process for making diarylamines | UNIROYAL, INC. (US) | 1984-03-28 | — | — | EP | disclosed |
| US-4431841-A | REACTING PRIMARY AROMATIC AMINES AND ALICYCLIC KETONES USING AN ACID PROMOTER AND A PLATINUM CATALYST | UNIROYAL, INC. (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | MAPK1, MAPKAPK2, MAPK7 | ACHE 4699/4885METAP1 2592/4885TSHR 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.